Pei Shi

机构：Nanyang Medical College

发表论文 19 篇 · 总被引 172 次 · h-index 2

代表论文

• Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial (2022 · ˜The œLancet. Gastroenterology & hepatology · 被引 88)
• miRNA-223 is a potential diagnostic and prognostic marker for osteosarcoma (2016 · Journal of bone oncology · 被引 78)
• Amelioration of T lymphocyte subsets, inflammatory factors and gastrointestinal function by traditional Chinese medicine rehabilitation management in postoperative chemotherapy for lung cancer (2025 · Journal of Medical Biochemistry · 被引 2)
• Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study. (2021 · Journal of Clinical Oncology · 被引 2)
• [ALC/AMC Value and Prognosis in Patients with Primary Follicular Lymphoma Treated with R-CHOP Chemotherapy]. (2018 · PubMed · 被引 2)
• Adonertinib (FHND9041) versus Afatinib as First-line Treatment for Advanced Non-small-cell Lung Cancer with EGFR Sensitive Mutation (FHND9041-Ⅲ-01): A Multi-centre, Open-label, Randomised Phase 3 Trial (2026 · Research Square)